Sep. 18, 2021

BMS-753426

sel. CCR2 chemokine receptor antagonist oral efficacy (25 mpk BID) in inflamm. models from PK opt. of prior candidate ACS Med. Chem. Lett., May 25, 2021 Bristol Myers Squibb, Princeton, NJ

drughunter.com
Drug Hunter Team
Loading...

twitterlinkedinemail

Other molecules you may be interested in